Akers Biosciences, Inc (AKER)

Etorro trading 970x250
Akers Biosciences, Inc (AKER) Logo

About Akers Biosciences, Inc

Akers Biosciences, Inc. focuses on the development of a vaccine candidate against SARS-CoV-2, a coronavirus causing a pandemic. It has a collaboration agreement with Premas Biotech PVT Ltd. The company was incorporated in 1989 and is headquartered in New York, New York. Address: 1185 Avenue of the Americas, New York, NY, United States, 10036

Akers Biosciences, Inc News and around…

Latest news about Akers Biosciences, Inc (AKER) common stock and company :

Akers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of Merger
16 Apr, 2021 FinancialContent

Akers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of Merger

50 Biggest Movers From Yesterday
14 Apr, 2021 FinancialContent

Gainers Mackinac Financial Corporation (NASDAQ: MFNC) shares surged 60.7% to close at $21.16 on Tuesday after the company, and ...

12 Health Care Stocks Moving In Tuesday's Intraday Session
13 Apr, 2021 FinancialContent

Gainers NovoCure (NASDAQ:NVCR) shares rose 42.08% to $187.38 during Tuesday's regular session. Trading volume for ...

Akers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Plans to Initiate COVID-19 Inflammatory Depression Trial
13 Apr, 2021 FinancialContent

Akers Biosciences, Inc. (NASDAQ: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending health lifespan and treating immune mediated illnesses, has reached an agreement with a major medical school to conduct a Phase 2 clinical trial to investigate the effectiveness of MYMD-1 to treat immune mediated depression in patients affected with COVID-19. MYMD believes that this investigator-initiated study is the first of its kind and addresses a significant unmet medical need.

Akers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Formation of Scientific Advisory Board
12 Apr, 2021 FinancialContent

Akers Biosciences, Inc. (Nasdaq: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, has completed the formation of its Scientific Advisory Board (SAB). The board will be chaired by Katharine Whartenby, Ph.D., associate professor at the Johns Hopkins University School of Medicine Department of Neurology, Department of Oncology and in Cellular and Molecular Medicine.

Akers Biosciences Announces Shareholder Meeting to Vote on Business Combination with MyMD Pharmaceuticals
22 Mar, 2021 FinancialContent

Akers Biosciences, Inc (Nasdaq: AKER), today announced that it has scheduled its general meeting of shareholders (the "Meeting”) to vote on the proposed business combination with MyMD Pharmaceuticals (“MyMD”). The meeting will be held on April 15, 2021 at 10:00 a.m., Eastern Time, and will be “virtual,” meaning that you can participate in the meeting online at www.virtualshareholdermeeting.com/AKER2021SM.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
02 Mar, 2021 FinancialContent

Gainers Strata Skin Sciences (NASDAQ:SSKN) shares moved upwards by 32.94% to $2.3 during Tuesday's pre-market ...

12 Health Care Stocks Moving In Wednesday's After-Market Session
24 Feb, 2021 FinancialContent

Gainers Dynatronics (NASDAQ:DYNT) stock rose 63.28% to $2.09 during Wednesday's after-market session. Dynatronics's trading ...

Akers Biosciences' Proposed Partner MyMD's Lead Candidate Inhibits Fibrotic Diseases-Associated Biomarkers
23 Feb, 2021 FinancialContent

Akers Biosciences Inc(NASDAQ:AKER) and its proposed merger partnerMyMD Pharmaceuticals Inchaveannounced ...

MyMD Pharmaceuticals Announces New Data on Its Lead Compound MYMD-1 from a Phenotypic Study Performed by Eurofins Discovery
23 Feb, 2021 FinancialContent

Akers Biosciences, Inc. (Nasdaq: AKER), with its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced new data from a study conducted by Eurofins Discovery Phenotypic Center of Excellence.

Study Identifies Effects of Temperature Changes on SARS-CoV-2 Transmission
18 Feb, 2021 FinancialContent

Akers Biosciences, Inc. (Nasdaq: AKER), with its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced a new study published in PLOS ONE authored by Adam Kaplin, M.D., Ph.D., Chief Scientific Officer of MyMD Pharmaceuticals, which demonstrates rising temperatures during spring and summer months are associated with slower rates of COVID-19 transmission, consistent with the behavior of a seasonal respiratory virus. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) belongs to a large family of human coronaviruses, most of which display increased transmission in cooler, less humid months, and decreased transmission in warmer and more humid months.

92 Biggest Movers From Yesterday
18 Feb, 2021 FinancialContent

Gainers Comstock Mining Inc. (NYSE: LODE) shares jumped 157.3% to close at $5.79 on Wednesday following news the company secured a ...

Akers Biosciences Responds to Erroneous Earnings Call Press Release
17 Feb, 2021 FinancialContent

Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER) confirmed that a press release issued earlier today with respect to an earnings call by Aker ASA was issued by a company wholly unrelated to the Company. The press release was errantly issued by the newswire services under the Company’s name. The Company has not scheduled any earnings calls. The Company is investigating how this error occurred and reserves all rights to pursue all appropriate remedies upon learning more about the cause of this error.

12 Health Care Stocks Moving In Wednesday's Intraday Session
17 Feb, 2021 FinancialContent

Gainers Onconova Therapeutics (NASDAQ:ONTX) stock rose 49.18% to $1.82 during Wednesday's regular session. Trading ...

70 Stocks Moving In Wednesday's Mid-Day Session
17 Feb, 2021 FinancialContent

Gainers TDH Holdings, Inc. (NASDAQ: PETZ) shares climbed 302% to $12.58 after jumping more than 25% on Tuesday. Comstock Mining ...

72 Biggest Movers From Yesterday
17 Feb, 2021 FinancialContent

Gainers Socket Mobile, Inc. (NASDAQ: SCKT) shares jumped 538.3% to close at $20.68 on Tuesday, driven by heavy volumes after the ...

12 Health Care Stocks Moving In Tuesday's After-Market Session
16 Feb, 2021 FinancialContent

Gainers Verastem (NASDAQ:VSTM) shares moved upwards by 16.53% to $2.89 during Tuesday's after-market session. This security ...

Mid-Afternoon Market Update: Wall Street Stocks Tumble; Crude Oil Down Over 1%
11 Feb, 2021 FinancialContent

Toward the end of trading Thursday, the Dow traded down 0.40% to 31,312.17 while the NASDAQ fell 0.04% to 13,966.26. The S&P also ...

50 Stocks Moving In Thursday's Mid-Day Session
11 Feb, 2021 FinancialContent

Gainers RCM Technologies, Inc. (NASDAQ: RCMT) shares rose 85.60% to $6.85 in mid-day trading after the company reported its ...

AKERS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of AKER and Encourages Investors to Contact the Firm
11 Feb, 2021 FinancialContent
44 Stocks Moving in Thursday's Pre-Market Session
11 Feb, 2021 FinancialContent

Gainers RCM Technologies, Inc. (NASDAQ: RCMT) shares rose 115.5% to $7.95 in pre-market trading after the company reported its ...

MERGER INVESTIGATION ALERT: Halper Sadeh LLP Encourages HMSY, HCAP, CBMG, and AKER Shareholders to Contact the Firm
02 Jan, 2021 FinancialContent
INVESTIGATION ALERT: Halper Sadeh LLP Continues to Investigate the Following Companies; Shareholders are Encouraged to Contact the Firm – IPHI, TNAV, NAV, AKER
12 Dec, 2020 FinancialContent
AKERS BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Akers Biosciences, Inc. - AKER
03 Dec, 2020 FinancialContent

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Akers Biosciences, Inc. (NasdaqCM: AKER) with MyMD Pharmaceuticals, Inc., pursuant to which Akers shareholders will end up owning just 20% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.

Looking For Hot Penny Stocks Today? 5 Making New December Highs
02 Dec, 2020 FinancialContent
Why These 4 Pharma Stocks Are Moving Today
02 Dec, 2020 FinancialContent

Akers Biosciences (NASDAQ: AKER) shares are trading higher on Wednesday after the company's proposed merger partner MyMD ...

Akers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Issuance of Key Patent
02 Dec, 2020 FinancialContent

Akers Biosciences, Inc. (Nasdaq: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”) was issued US Pat. No. 10,835,523 B2, titled “Method of Regulating Tumor Necrosis Factor-Alpha (TNF-α) for Treating Cancers, Autoimmune Disorders, and Other Disorders Associated with Chronic Inflammation” by the United States Patent & Trademark Office (USPTO). The patent is a continuation of U.S. patent application No. 15/558,094, which was granted as U.S. Patent No. 10,588,899 with claims for treating diabetes.

Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm – NAV, UROV, HDS, AKER
01 Dec, 2020 FinancialContent
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of NAV, UROV, AKER, and EMIS Mergers
01 Dec, 2020 FinancialContent
Halper Sadeh LLP Continues to Investigate the Following Mergers; Investors are Encouraged to Contact the Firm – UROV, HDS, AKER, GV
26 Nov, 2020 FinancialContent

Akers Biosciences, Inc (AKER) is a NASDAQ Common Stock listed in , ,

970x250